These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34540661)

  • 21. Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
    Bernstein-Molho R; Kaufman B; Ben David MA; Sklair-Levy M; Feldman DM; Zippel D; Laitman Y; Friedman E
    Breast; 2020 Feb; 49():81-86. PubMed ID: 31760168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
    Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
    Pellegrino B; Bella M; Michiara M; Zanelli P; Naldi N; Porzio R; Bortesi B; Boggiani D; Zanoni D; Camisa R; Neri TM; Pinto C; Musolino A
    Acta Biomed; 2016 May; 87(1):54-63. PubMed ID: 27163896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ductal carcinoma in situ in BRCA mutation carriers.
    Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
    J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
    Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
    Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
    Bayraktar S; Elsayegh N; Gutierrez Barrera AM; Lin H; Kuerer H; Tasbas T; Muse KI; Ready K; Litton J; Meric-Bernstam F; Hortobagyi GN; Albarracin CT; Arun B
    Cancer; 2012 Mar; 118(6):1515-22. PubMed ID: 22009639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
    Chiba A; Hoskin TL; Hallberg EJ; Cogswell JA; Heins CN; Couch FJ; Boughey JC
    Ann Surg Oncol; 2016 Oct; 23(10):3232-8. PubMed ID: 27338744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    Ibrahim M; Yadav S; Ogunleye F; Zakalik D
    BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
    Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B
    Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Profiling Comparison of Germline
    Huang X; Shao D; Wu H; Zhu C; Guo D; Zhou Y; Chen C; Lin Y; Lu T; Zhao B; Wang C; Sun Q
    Front Oncol; 2020; 10():583314. PubMed ID: 33194720
    [No Abstract]   [Full Text] [Related]  

  • 33. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of
    Pogoda K; Niwińska A; Sarnowska E; Nowakowska D; Jagiełło-Gruszfeld A; Siedlecki J; Nowecki Z
    J Oncol; 2020; 2020():8545643. PubMed ID: 32322271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
    Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH
    World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    van der Groep P; van Diest PJ; Smolders YH; Ausems MG; van der Luijt RB; Menko FH; Bart J; de Vries EG; van der Wall E
    PLoS One; 2013; 8(2):e56055. PubMed ID: 23409121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 38. 'Earlier than Early' Detection of Breast Cancer in Israeli
    Anaby D; Shavin D; Zimmerman-Moreno G; Nissan N; Friedman E; Sklair-Levy M
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.
    Le-Petross HT; Whitman GJ; Atchley DP; Yuan Y; Gutierrez-Barrera A; Hortobagyi GN; Litton JK; Arun BK
    Cancer; 2011 Sep; 117(17):3900-7. PubMed ID: 21365619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of
    Huang X; Liu JQ; Zhou YD; Xu Y; Chen C; Wang X; Cao X; Yao R; Sun Q
    Ann Transl Med; 2020 Sep; 8(18):1183. PubMed ID: 33241032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.